We De-LIVER on More Livers: Hepatitis B-Positive Transplant Donors and Recipients
Currently, there are over 12,000 people on the waiting list to receive a liver in the US, and around 17 people die each day waiting on a transplant. Because of this severe organ shortage in the US, organs that were previously rejected due to infection with different types of hepatitis are now being considered and used, requiring additional treatment for hepatitis B to protect the new liver being transplanted. Guidelines for treatment of hepatitis B infected recipients and donors is addressed by two guidelines: American Society of Transplantation (AST) and American Association for the Study of Liver Diseases (AASLD). There are antiviral agents and hepatitis B immunoglobulin available for treatment of hepatitis B. However, there are often many questions about when to use which agents. This presentation will review the primary literature behind the use of antivirals and hepatitis B immunoglobulin in hepatitis B positive transplant recipients and donors.
Target Audience
- Pharmacists
- Pharmacy technicians
Learning Objectives
Pharmacist learning objectives
- Discuss diagnosis of hepatitis B
- Compare the agents used to treat hepatitis B in the setting of patients receiving a liver transplant
- Evaluate the literature on the use of antiviral agents and hepatitis B immunoglobulin to prevent hepatitis B in patients receiving a liver transplant and recognize their place in practice
Pharmacy technician learning objectives
- Recognize brand/generic names of the antiviral agents used in the treatment of hepatitis B
- Identify the different dosage forms of the antiviral agents
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users.pdf | 157.72 KB |
Instructions for Obtaining CE Credit - We De-LIVER on More Livers.docx | 29.6 KB |
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE - Attendance